July 19, 2024 6:52am

Considering profitability, revenue, trial status, liabilities, runways, growth potential as EPS and estimates come into focus

A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations

Never leave an investor uninformed

The week is to end and be subject to review and objectification 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday

 

Friday: The pre-open Dow futures are DOWN -0.14% or (-57 points), the S&P futures are UP +0.04% or (+5 points) as the Nasdaq futures are DOWN -0.01% or (-2 points)

  • Stock futures were mixed and barely moving on Friday,
  • European markets lower amid global IT outage,
  • Asia-Pacific markets fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday: The Dow closed DOWN -533.19 points or -1.29%, the S&P closed DOWN -43.70 points or -0.78% while the Nasdaq closed DOWN -125.70 points or -0.70%

 

RegMed Investors (RMi) Closing bell: “increasing turbulence In the cell and gene therapy sector. It’s more than profit taking, showing the magnitude of what we’ve seeing as rotation.” … https://www.regmedinvestors.com/articles/13551

 

Q3/24:

  • July: 1 market holiday. 1 day off, 4 negative, 1 neutral (previous Friday) and 7 positive  closes

Q2/24: 

  • June – 1 market holiday, 7 positive and 1 negative closes
  • May – 1 holiday, 11 positive and 11 negative closes
  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Yet again, I am passing on forecasting the daily indications as expectations are in focus as expectation in the aftermarket fluctuated while the pre-open waits for the all-clear alarm …  it is still a mix of ups, downs and just unknowns.

  • Network issuses?

 

The BOTTOM LINE: On Thursday and Wednesday, the cell and gene therapy sector tanked after Tuesday, Monday and Friday's rallies sector gains.

  • For the balance of the month, investors will focus most on share pricing in regard to earnings EPS and meeting expectations!

 

July week to date: advance/decline lines …

  • Thursday ended with a negative close of 3 incliners, 30 decliners and 2 flats
  • Wednesday ended with a negative close of 4 incliners, 29 decliners and 2 flats
  • Tuesday’s advance/decline line ended with a positive close of 30 incliners, 2 decliners and 3 flats
  • (7/15) Monday ended with a positive close of 21 incliners, 9 decliners and 6 flats
  • Friday ended with a positive close of 22 incliners, 11 decliners and 2 flats
  • Thursday ended with a positive close of 31 incliners, 2 decliners and 2 flats
  • Wednesday ended with a positive close of 23 incliners, 10 decliners and 2 flats
  • Tuesday ended with a positive close of 19 incliners, 12 decliners and 4 flats
  • (7/8) Monday ended positive with 24 incliners, 8 decliners and 3 flats
  • Friday ended with a neutral close of 16 incliners, 16 decliners and 3 flats
  • Thursday was a market holiday
  • Wednesday was a day off
  • Tuesday ended with a negative close of 6 incliners, 19 decliners and 3 flats
  • (7/1) Monday ended with a negative close of 13 incliners, 19 decliners and 3 flats

 

“Stuff” happens:

  • The stock market rally showed across-the-board losses in key indexes and ETFs.
  • Indexes saw broad losses Thursday as the Dow and small caps led the declines while the Nasdaq fell again, but pared losses near the close.
  • The 10-year Treasury yield rose 4.5 basis points to 4.19%, bouncing from Wednesday's four-month low.
  • US weekly jobless claims rose more than expected as leadership from the Fed has expressed confidence in bringing inflation down.
  • The healthcare sector (XLV) slumped today, leading in sector losses and dropping by over 2%.
  • The run that small caps (^RUT) has seen in the past few days has begun to stall out, erasing much of the gains from earlier in the week.

 

Due “dates” are DUE soon for Q2 LPS (loss per-share) boding releases:

  • Sage Therapeutics (SAGE) on Wednesday, 7/31
  • MiMedx (MDXG) on Wednesday, 7/31
  • Vericel (VCEL) on Thursday, 8/1
  • Alnylam Pharmaceuticals (ALNY) on Thursday, 8/1
  • Blueprint Medicine (BPMC) on Thursday, 8/1

 

Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts can filter out or lessen the noise of back-and-forth share pricing from sector rotation.

  • The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.